(Rac)-PT2399 is primarily utilized in research settings to study the hypoxia-inducible factor (HIF) pathway, which plays a critical role in cellular responses to low oxygen levels. It acts as a potent inhibitor of HIF-2α, making it a valuable tool for investigating the mechanisms of hypoxia-related diseases such as cancer, particularly renal cell carcinoma. By blocking HIF-2α activity, it helps researchers understand tumor growth, angiogenesis, and metabolic adaptation in hypoxic environments. Additionally, it is used to explore potential therapeutic strategies targeting HIF-2α in various cancers and other conditions influenced by hypoxia. Its role in preclinical studies aids in the development of novel treatments for diseases driven by abnormal HIF signaling.